- Home
- LSF vs AGEN Comparison
LSF vs AGEN Comparison
Compare LSF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- AGEN
- Stock Information
- Founded
- LSF 2015
- AGEN 1994
- Country
- LSF United States
- AGEN United States
- Employees
- LSF N/A
- AGEN N/A
- Industry
- LSF Packaged Foods
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSF Consumer Staples
- AGEN Health Care
- Exchange
- LSF Nasdaq
- AGEN Nasdaq
- Market Cap
- LSF 65.5M
- AGEN 87.7M
- IPO Year
- LSF 2020
- AGEN 2000
- Fundamental
- Price
- LSF $7.38
- AGEN $7.27
- Analyst Decision
- LSF Strong Buy
- AGEN Buy
- Analyst Count
- LSF 2
- AGEN 4
- Target Price
- LSF $12.00
- AGEN $13.00
- AVG Volume (30 Days)
- LSF 27.6K
- AGEN 1.4M
- Earning Date
- LSF 08-06-2025
- AGEN 08-07-2025
- Dividend Yield
- LSF N/A
- AGEN N/A
- EPS Growth
- LSF N/A
- AGEN N/A
- EPS
- LSF N/A
- AGEN N/A
- Revenue
- LSF $45,040,358.00
- AGEN $99,524,000.00
- Revenue This Year
- LSF $23.40
- AGEN $12.69
- Revenue Next Year
- LSF $20.11
- AGEN N/A
- P/E Ratio
- LSF N/A
- AGEN N/A
- Revenue Growth
- LSF 25.04
- AGEN N/A
- 52 Week Low
- LSF $3.40
- AGEN $1.38
- 52 Week High
- LSF $10.90
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- LSF 57.20
- AGEN 68.42
- Support Level
- LSF $6.03
- AGEN $4.78
- Resistance Level
- LSF $6.74
- AGEN $6.20
- Average True Range (ATR)
- LSF 0.31
- AGEN 0.62
- MACD
- LSF 0.05
- AGEN 0.10
- Stochastic Oscillator
- LSF 66.67
- AGEN 98.90
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).